Intrapleural interleukin-2 induces nitric oxide production in pleural effusions from malignant mesothelioma: a possible mechanism of interleukin-2-mediated cytotoxicity?

Lung Cancer. 2002 Nov;38(2):159-62. doi: 10.1016/s0169-5002(02)00187-3.

Abstract

Due to the frequent use of intrapleural interleukin-2 (IL-2) to treat pleural effusions from malignant mesothelioma (MMe), we measured nitric oxide (NO) end product nitrite (NO(2)(-)) in pleural effusions of 12 MMe patients with chronic or chronic-relapsing pleurisy. Through high performance liquid chromatography analysis, NO(2)(-) was found in the initial pleural fluid sample of all patients (156.25 pmol ml(-1)), and increased significantly following IL-2 intrapleural instillation, both at 24 (589.91 pmol ml(-1), P < or = 0.0005) and 48 h (756 pmol ml(-1), P< or = 0.0005). Even though it is difficult to argue if the large amounts of NO end product NO(2)(-) we observed is produced by IL-2-stimulated and recruited immune cells, by MMe cells themselves, or by both, it is possible that NO could contribute to the complex antitumor activity of IL-2.

Publication types

  • Clinical Trial

MeSH terms

  • Aged
  • Antineoplastic Agents / administration & dosage
  • Antineoplastic Agents / adverse effects*
  • Antineoplastic Agents / pharmacology
  • Chromatography, High Pressure Liquid
  • Dose-Response Relationship, Drug
  • Female
  • Humans
  • Immunity, Cellular / drug effects
  • Interleukin-2 / administration & dosage
  • Interleukin-2 / adverse effects*
  • Interleukin-2 / pharmacology
  • Male
  • Mesothelioma / drug therapy*
  • Mesothelioma / pathology
  • Middle Aged
  • Nitric Oxide / analysis*
  • Nitrites / analysis*
  • Pleural Effusion / drug therapy*
  • Pleural Effusion / etiology*

Substances

  • Antineoplastic Agents
  • Interleukin-2
  • Nitrites
  • Nitric Oxide